Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Mesothelioma | Research

Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma

Authors: Jinzhi Lai, Hainan Yang, Tianwen Xu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Malignant mesothelioma (MM) is a relatively rare and highly lethal tumor with few treatment options. Thus, it is important to identify prognostic markers that can help clinicians diagnose mesothelioma earlier and assess disease activity more accurately. Alternative splicing (AS) events have been recognized as critical signatures for tumor diagnosis and treatment in multiple cancers, including MM.

Methods

We systematically examined the AS events and clinical information of 83 MM samples from TCGA database. Univariate Cox regression analysis was used to identify AS events associated with overall survival. LASSO analyses followed by multivariate Cox regression analyses were conducted to construct the prognostic signatures and assess the accuracy of these prognostic signatures by receiver operating characteristic (ROC) curve and Kaplan–Meier survival analyses. The ImmuCellAI and ssGSEA algorithms were used to assess the degrees of immune cell infiltration in MM samples. The survival-related splicing regulatory network was established based on the correlation between survival-related AS events and splicing factors (SFs).

Results

A total of 3976 AS events associated with overall survival were identified by univariate Cox regression analysis, and ES events accounted for the greatest proportion. We constructed prognostic signatures based on survival-related AS events. The prognostic signatures proved to be an efficient predictor with an area under the curve (AUC) greater than 0.9. Additionally, the risk score based on 6 key AS events proved to be an independent prognostic factor, and a nomogram composed of 6 key AS events was established. We found that the risk score was significantly decreased in patients with the epithelioid subtype. In addition, unsupervised clustering clearly showed that the risk score was associated with immune cell infiltration. The abundances of cytotoxic T (Tc) cells, natural killer (NK) cells and T-helper 17 (Th17) cells were higher in the high-risk group, whereas the abundances of induced regulatory T (iTreg) cells were lower in the high-risk group. Finally, we identified 3 SFs (HSPB1, INTS1 and LUC7L2) that were significantly associated with MM patient survival and then constructed a regulatory network between the 3 SFs and survival-related AS to reveal potential regulatory mechanisms in MM.

Conclusion

Our study provided a prognostic signature based on 6 key events, representing a better effective tumor-specific diagnostic and prognostic marker than the TNM staging system. AS events that are correlated with the immune system may be potential therapeutic targets for MM.

Available only for authorised users

Arif Q, Husain AN. Malignant mesothelioma diagnosis. Archives of pathology & laboratory medicine. 2015;139(8):978–80. https://doi.org/10.5858/arpa.2013-0381-RA.CrossRef

Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21(st) century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–38. https://doi.org/10.21037/tlcr.2019.11.11.CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Thomas A, Karakattu S, Cagle J, Hoskere G. Malignant pleural mesothelioma epidemiology in the United States from 2000 to 2016. Cureus. 2021;13(4):e14605. https://doi.org/10.7759/cureus.14605.CrossRefPubMedPubMedCentral

Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343–73. https://doi.org/10.1200/JCO.2017.76.6394.CrossRefPubMed

Woodard GA, Jablons DM. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S86–91. https://doi.org/10.21037/tlcr.2020.01.08.CrossRefPubMedPubMedCentral

Yoshikawa Y, Emi M, Nakano T, Gaudino G. Mesothelioma developing in carriers of inherited genetic mutations. Transl Lung Cancer Res. 2020;9(Suppl 1):S67–76. https://doi.org/10.21037/tlcr.2019.11.15.CrossRefPubMedPubMedCentral

Ule J, Blencowe BJ. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol Cell. 2019;76(2):329–45. https://doi.org/10.1016/j.molcel.2019.09.017.CrossRefPubMed

Manning K, Cooper T. The roles of RNA processing in translating genotype to phenotype. Nat Rev Mol Cell Biol. 2017;18(2):102–14. https://doi.org/10.1038/nrm.2016.139.CrossRefPubMed

10.

Mazin P, Khaitovich P, Cardoso-Moreira M, Kaessmann H. Alternative splicing during mammalian organ development. Nat Genet. 2021;53(6):925–34. https://doi.org/10.1038/s41588-021-00851-w.CrossRefPubMedPubMedCentral

11.

Baralle F, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18(7):437–51. https://doi.org/10.1038/nrm.2017.27.CrossRefPubMedPubMedCentral

12.

Akerman M, Fregoso OI, Das S, Ruse C, Jensen MA, Pappin DJ, et al. Differential connectivity of splicing activators and repressors to the human spliceosome. Genome Biol. 2015;16(1):119. https://doi.org/10.1186/s13059-015-0682-5.CrossRefPubMedPubMedCentral

13.

Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, et al. Widespread expansion of protein interaction capabilities by alternative splicing. Cell. 2016;164(4):805–17. https://doi.org/10.1016/j.cell.2016.01.029.CrossRefPubMedPubMedCentral

14.

Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E. The functional impact of alternative splicing in Cancer. Cell Rep. 2017;20(9):2215–26. https://doi.org/10.1016/j.celrep.2017.08.012.CrossRefPubMed

15.

Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in Cancer susceptibility genes in malignant mesothelioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(28):2863–71. https://doi.org/10.1200/JCO.2018.78.5204.CrossRef

16.

Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–16. https://doi.org/10.1038/ng.3520.CrossRefPubMed

17.

Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, et al. A p120 catenin isoform switch affects rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem. 2008;283(26):18344–54. https://doi.org/10.1074/jbc.M801192200.CrossRefPubMedPubMedCentral

18.

Nancy MM, Nora RM, Maricruz AR, Eduardo MG, Rebeca MC. Alternative Splicing as a Target for Cancer Treatment. Int J Mol Sci. 2018;19(2):545.CrossRef

19.

Bergsma AJ, Wal EVD, Broeders M, Ploeg ATVD, Pijnappel WWMP. Alternative splicing in genetic diseases: improved diagnosis and novel treatment options. Int Rev Cell Mol Biol. 2017;335:85.CrossRefPubMed

20.

Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene. 2014;33(46):5311–8. https://doi.org/10.1038/onc.2013.533.CrossRefPubMed

21.

Smart A, Margolis C, Pimentel H, He M, Miao D, Adeegbe D, et al. Intron retention is a source of neoepitopes in cancer. Nat Biotechnol. 2018;36(11):1056–8. https://doi.org/10.1038/nbt.4239.CrossRefPubMedPubMedCentral

22.

Wu Z, Chen H, Liang Y, Luo W, Deng F, Zeng F. Alternative splicing implicated in immunity and prognosis of colon adenocarcinoma. Int Immunopharmacol. 2020;89(Pt B):107075.CrossRefPubMed

23.

Ryan M, Wong WC, Brown R, Akbani R, Su X, Broom B, et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 2016;44(D1):D1018–22. https://doi.org/10.1093/nar/gkv1288.CrossRefPubMed

24.

Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–7. https://doi.org/10.1089/omi.2011.0118.CrossRefPubMedPubMedCentral

25.

Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

26.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein science : a publication of the Protein Society. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715.CrossRef

27.

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–d551. https://doi.org/10.1093/nar/gkaa970.CrossRefPubMed

28.

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95. https://doi.org/10.1016/j.immuni.2013.10.003.CrossRefPubMed

29.

Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in Cancer immunotherapy. Adv Sci (Weinh). 2020;7(7):1902880. https://doi.org/10.1002/advs.201902880.CrossRef

30.

Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 Cancer types. Cell Rep. 2018;23(1):282–96 e284. https://doi.org/10.1016/j.celrep.2018.01.088.CrossRefPubMedPubMedCentral

31.

Kim P, Yang M, Yiya K, Zhao W, Zhou X. ExonSkipDB: functional annotation of exon skipping event in human. Nucleic Acids Res. 2019;48(D1):D896–907.PubMedCentral

32.

Yu S, Hu C, Liu L, Cai L, Du X, Yu Q, et al. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer. J Transl Med. 2020;18(1):286. https://doi.org/10.1186/s12967-020-02454-1.CrossRefPubMedPubMedCentral

33.

Wang L, Bi J, Li X, Wei M, He M, Zhao L. Prognostic alternative splicing signature reveals the landscape of immune infiltration in pancreatic Cancer. J Cancer. 2020;11(22):6530–44. https://doi.org/10.7150/jca.47877.CrossRefPubMedPubMedCentral

34.

Marques M, Tranchant R, Risa-Ebri B, Suarez-Solis ML, Fernandez LC, Carrillo-de-Santa-Pau E, et al. Combined MEK and PI3K/p110beta inhibition as a novel targeted therapy for malignant mesothelioma displaying Sarcomatoid features. Cancer Res. 2020;80(4):843–56. https://doi.org/10.1158/0008-5472.CAN-19-1633.CrossRefPubMed

35.

David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010;24(21):2343–64. https://doi.org/10.1101/gad.1973010.CrossRefPubMedPubMedCentral

36.

Urbanski LM, Leclair N, Anczukow O. Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley interdisciplinary reviews RNA. 2018;9(4):e1476. https://doi.org/10.1002/wrna.1476.CrossRefPubMedPubMedCentral

37.

Bonnal S, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17(8):457–74. https://doi.org/10.1038/s41571-020-0350-x.CrossRefPubMed

38.

Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34(2):211–24 e216. https://doi.org/10.1016/j.ccell.2018.07.001.CrossRefPubMed

39.

Teng H, Mao F, Liang J, Xue M, Wei W, Li X, et al. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics. 2018;8(16):4345–58. https://doi.org/10.7150/thno.26862.CrossRefPubMedPubMedCentral

40.

Xiong Y, Deng Y, Wang K, Zhou H, Zheng X, Si L, et al. Profiles of alternative splicing in colorectal cancer and their clinical significance: a study based on large-scale sequencing data. EBioMedicine. 2018;36:183–95. https://doi.org/10.1016/j.ebiom.2018.09.021.CrossRefPubMedPubMedCentral

41.

Zhao D, Zhang C, Jiang M, Wang Y, Liang Y, Wang L, et al. Survival-associated alternative splicing signatures in non-small cell lung cancer. Aging. 2020;12(7): 5878–93.

42.

Xue D, Cheng P, Jiang J, Ren Y, Wu D, Chen W. Systemic analysis of the prognosis-related RNA alternative splicing signals in melanoma. Med Sci Monit. 2020;26:e921133.PubMedPubMedCentral

43.

Wu F, Chen Q, Liu C, Duan X, Hu J, Liu J, et al. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma. Cancer Med. 2020;9(6):2171–80. https://doi.org/10.1002/cam4.2875.CrossRefPubMedPubMedCentral

44.

Wang Y, Chen SX, Rao X, Liu Y. Modulator-dependent RBPs changes alternative splicing outcomes in kidney Cancer. Front Genet. 2020;11:265. https://doi.org/10.3389/fgene.2020.00265.CrossRefPubMedPubMedCentral

45.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer discovery. 2018;8(12):1548–65. https://doi.org/10.1158/2159-8290.CD-18-0804.CrossRefPubMedPubMedCentral

46.

Sneddon S, Patch AM, Dick IM, Kazakoff S, Pearson JV, Waddell N, et al. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer. 2017;17(1):396. https://doi.org/10.1186/s12885-017-3382-6.

47.

Creaney J, Robinson BWS. Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment. Chest. 2017;152(1):143–9.

48.

Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers:a systematic review. Br J Cancer. 2017;116(6):731–41.

49.

Martinez NM, Lynch KW. Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn. Immunol Rev. 2013;253(1):216–36. https://doi.org/10.1111/imr.12047.CrossRefPubMedPubMedCentral

50.

Wang Y, Zhang H, Jiao B, Nie J, Li X, Wang W, et al. The roles of alternative splicing in tumor-immune cell interactions. Curr Cancer Drug Targets. 2020;20(10):729–40. https://doi.org/10.2174/1568009620666200619123725.CrossRefPubMed

51.

Hoyos LE, Abdel-Wahab O. Cancer-specific splicing changes and the potential for splicing-derived Neoantigens. Cancer Cell. 2018;34(2):181–3. https://doi.org/10.1016/j.ccell.2018.07.008.CrossRefPubMedPubMedCentral

52.

Torres-Rosell J, Machín F, Farmer S, Jarmuz A, Eydmann T, Dalgaard JZ, et al. SMC5 and SMC6 genes are required for the segregation of repetitive chromosome regions. Nat Cell Biol. 2005;7(4):412–9. https://doi.org/10.1038/ncb1239.CrossRefPubMed

53.

Zhuo Y, Liu Z, Wan S, Cai Z, Xie J, Cai Z, et al. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer. Biomed Pharmacother. 2018;102:531–8.CrossRefPubMed

54.

Wang J, Wu H, Shen W, Xu D, Ruan T, Tao G, et al. SRPK2 promotes the growth and migration of the colon cancer cells. Gene. 2016;586(1):41–7. https://doi.org/10.1016/j.gene.2016.03.051.CrossRefPubMed

55.

Liu X, Si W, Liu X, He L, Ren J, Yang Z, et al. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component. Mol Cancer. 2017;16(1):175. https://doi.org/10.1186/s12943-017-0744-2.CrossRefPubMedPubMedCentral

56.

Wang BD, Lee NH. Aberrant RNA Splicing in Cancer and Drug Resistance. Cancers. 2018;10(11):1–24.

57.

Yoshida K, Ogawa S. Splicing factor mutations and cancer. Wiley interdisciplinary reviews RNA. 2014;5(4):445–59. https://doi.org/10.1002/wrna.1222.CrossRefPubMed

58.

Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, et al. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine. 2019;39:215–25. https://doi.org/10.1016/j.ebiom.2018.12.025.CrossRefPubMed

59.

Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33(3):306–12. https://doi.org/10.1038/nbt.3080.CrossRefPubMed

60.

Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, et al. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(10):1089–95. https://doi.org/10.1097/JTO.0b013e3181839693.CrossRef

61.

Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol. 2014;7(1):15. https://doi.org/10.1186/1756-8722-7-15.CrossRefPubMedPubMedCentral

62.

Vinayagam A, Stelzl U, Foulle R, Plassmann S, Zenkner M, Timm J, et al. A directed protein interaction network for investigating intracellular signal transduction. Sci Signal. 2011;4(189):rs8.CrossRefPubMed

63.

Hosono N, Makishima H, Przychodzen B, Singh J, Maciejewski JP. Spliceosomal gene LUC7L2 mutation causes Missplicing and alteration of gene expression in myeloid neoplasms. Blood. 2013;122(21):470. https://doi.org/10.1182/blood.V122.21.470.470.CrossRef

Title: Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma
Authors: Jinzhi Lai
Hainan Yang
Tianwen Xu
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Mesothelioma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08548-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer

Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome

In vivo assessment of prostate cancer response using quantitative ultrasound characterization of ultrasonic scattering properties

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer

Prognostic role of DFNA5 in head and neck squamous cell carcinoma revealed by systematic expression analysis

A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules

Keynote webinar | Spotlight on antibody–drug conjugates in cancer